Preventing opioid-induced constipation at opioid start: what 2024-26 data show

In a 2025 Japanese retrospective cohort of 928 inpatients with cancer starting a strong opioid, 536 remained after propensity matching; constipation within one week occurred in 48.1% with prophylactic laxatives and 48.9% without ^[1]. A 2024 randomized trial (n=99) enrolled adults with cancer starting a first regular strong opioid at four academic hospitals in Japan, most of them outpatients ^[2]. In that 2024 trial, one peripherally acting mu-opioid receptor antagonist (PAMORA) given from the first opioid dose produced a Bowel Function Index score below 28.8 at day 14 (the primary endpoint; lower scores mean better function) in 64.6% versus 17.0% with placebo ^[2]. The 2025 cohort and the 2024 trial differ in setting, endpoint and comparator, so neither ranks one approach against the other ^[1][2].

What do the 2026 guidance documents say?

Opioid-induced constipation (OIC) is described in the 2026 German expert consensus as an adverse effect that, unlike other opioid effects, usually does not improve over time ^[3]. That 2026 German consensus, in which 12 statements achieved consensus with at least 90% agreement, endorsed early laxative therapy, with a stepwise move to a PAMORA after an inadequate response, and noted that three PAMORAs are approved for OIC in Europe ^[3]. The 2026 Taiwan expert guidance states that management begins before opioid initiation, with patient education, a baseline bowel assessment, and prophylactic laxatives in high-risk settings ^[4]. The Taiwan guidance pairs Rome IV criteria with the Bowel Function Index for diagnosis and monitoring, and places reassessment one to two weeks after first-line therapy for diagnosed OIC ^[4].

What does the evidence on prevention show?

Conventional laxatives. In the 2025 cohort, the odds ratio for constipation with prophylactic laxatives was 0.97 (95% CI 0.69 to 1.36), an interval that includes both lower and higher odds; the German consensus and Taiwan guidance are expert recommendations, not results of this comparison ^[1][3][4]. In the 2025 cohort, age of 65 years or older (odds ratio [OR] 1.53, 95% CI 1.07 to 2.19) and an Eastern Cooperative Oncology Group (ECOG) performance status of 3 or more (OR 1.69, 95% CI 1.04 to 2.77) were associated with higher constipation incidence ^[1].

One PAMORA, given at opioid start. In the 2024 trial, the between-group difference in day-14 Bowel Function Index response was 47.6 percentage points (95% CI 30.3 to 64.8) ^[2]. The 2024 trial and the single-center 2026 cohort described below each studied the same PAMORA, so their results describe that agent and are not class-wide estimates ^[2][5].

Where is the evidence uncertain?

The 2025 laxative cohort was retrospective and included only patients hospitalized for more than a week after opioid initiation ^[1]. The 2024 trial's primary endpoint was measured at day 14 of protocol treatment, so it does not address later constipation ^[2]. Authors of the 2024 trial disclosed pharmaceutical speaker honoraria ^[2].

In a 2026 single-center retrospective cohort of 101 patients who started oxycodone in 2017 to 2018, additional laxative initiation or dose escalation was recorded within 7 days of starting the PAMORA in 6 of 31 patients (19.4%) when the PAMORA began alongside the opioid versus 2 of 70 (2.9%) when it was added later for recognized constipation (p=0.010) ^[5]. The groups differ in why the PAMORA was started, and starting it with the opioid did not eliminate early laxative adjustment ^[5]. That 2026 cohort reported diarrhea-related discontinuation within 28 days in 2 of 31 (6.5%) versus 6 of 70 (8.6%) ^[5].

At the point of care: what to check

• Laxative exposure: whether a laxative was started with the opioid, and whether constipation was recorded in the first week, the window in which the 2025 cohort found no detectable difference with prophylactic laxatives ^[1].
• Baseline bowel function: whether a baseline bowel assessment was recorded before the opioid started, and whether the Bowel Function Index is in use for diagnosis and monitoring ^[4].
• Risk markers: age of 65 years or older and an ECOG performance status of 3 or more carried higher constipation odds in the 2025 cohort ^[1].
• Reassessment window: whether bowel function was reassessed one to two weeks after first-line therapy for diagnosed OIC ^[4].